Gregory H. Bailey - 28 Apr 2022 Form 4 Insider Report for Biohaven Pharmaceutical Holding Co Ltd.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 28 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Apr 2022, 20:59:31 UTC
Prior SEC filing: 23 Jun 2021
Next SEC filing: 22 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ George Clark, Attorney-in-Fact

Key filing fact

Gregory H. Bailey filed Form 4 for Biohaven Pharmaceutical Holding Co Ltd. on 29 Apr 2022.

Key facts

This page summarizes Gregory H. Bailey's Form 4 filing for Biohaven Pharmaceutical Holding Co Ltd..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Apr 2022, 20:59.

Change

Previous filing in this sequence was filed on 23 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BHVN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +8,239
Change %
Price: $0.000000
Shares after: 8,239
Date: 28 Apr 2022
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 8,239
Exercise price: $97.74
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC remarks

Exhibit List: Exhibit 24: Power of attorney